Opinion|Videos|October 18, 2024
Long-term NMOSD Data
Author(s)Sean Pittock, MD
Sean Pittock, MD, discusses the long-term efficacy and safety results of other FDA-approved treatments for neuromyelitis optica spectrum disorder, including satralizumab, inebilizumab, and the off-label use of rituximab.
Advertisement
Video content above is prompted by the following:
Can you also comment on long-term efficacy and safety results with other FDA-approved treatments, including satralizumab, inebilizumab, and off-label use of rituximab?
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Daridorexant Provides Relief for Insomnia in Women During Menopausal Transition
2
Stem Cells of Secondary Progressive Multiple Sclerosis Drive Increased Proinflammatory T-Cell Activity
3
New Study Finds Link Between Gut Hormone GLP-1 and NMOSD Symptoms, Paving Way for Targeted Treatments
4
RELIEV-CM Pilot Study Data Further Supports ShiraTronics’ Neuromodulation Device to Treat Chronic Migraine
5